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A B S T R A C T
The aim of this study was to produce fine particles with different corrugated degree of surface
by spray-drying and to investigate the effect of surface morphology on in vitro aerosol per-
formance of the particles within HFA 134a based metered dose formulations. Compositions
of rizatriptan and scutellarin were spray-dried using different spray-drying parameters, and
particles were suspended within HFA 134a.The surface morphology were determined using
scanning electron microscopy (SEM), while the aerodynamic performance of MDIs was evalu-
ated using a next generation pharmaceutical impactor. The surface morphology of spray-
dried particles could vary from smooth to moderately corrugated, and to raisin-like depending
upon spray-drying parameters and preparation compositions. In general, increasing inlet
temperature, decreasing feed concentration and/or adding leucine to the feed solution tended
to increase the corrugated degree of particle surface. Deposition results indicated that raisin-
like particle based MDIs for all compositions of the two drugs produced significantly better
aerodynamic performance in terms of fine particle fractions and mass median aerody-
namic diameters relative to the formulations of the corresponding smooth or slightly
corrugated particles when the particle compositions were the same.The present results dem-
onstrated that wrinkled particles increased fine particle fractions within surfactant-free MDI
formulations.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-









Suspension metered dose inhalers (MDIs) are generally sus-
ceptible to physical instability such as phase separation,
flocculation and aggregation [1,2]. As a result, surfactants have
been often incorporated into propellants to increase physical
stability of chlorofluorocarbons (CFC) based MDIs [1]. Due to
the ozone-depletion effects, CFCs are to be totally banned for
MDI until 2015 [3] under the terms of the Montreal Protocol.
Hence, HFA-134a and HFA-227 have been utilized as alterna-
tive propellants to CFCs [4]. However, surfactants effective in
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stabilizing drug suspensions in CFCs are no longer capable of
stabilizing HFA based MDIs since those surfactants have limited
solubility in the latter propellants. In order to minimize physi-
cal instability associated with dispersions in HFA, previous
studies had added HFA-miscible cosolvents such as ethanol to
increase the solubility of surfactants and/or utilized HFA-
soluble surfactants, such as Brij [5], fluorinated surfactants [6–8];
and polyoxyethylene glyceryl derivatives [9]. However, HFA-
soluble surfactants are yet to be available until their safety has
been demonstrated. On the other hand, the inclusion of co-
solvents presented certain disadvantages; for example, the
low volatility of ethanol may decrease system vapor pressure
and lower the fine particle fraction [10,11], and the change in
solvency resulting from the addition of co-solvents may po-
tentially solubilize drug substances and destabilize the
suspension [12].
Breviscapine is the active component of Erigeron breviscopus
(Van.) and has been used in the treatment of cerebral infarc-
tion, angina pectoris, and vertebrobasilar insufficiency. However,
its wider application was limited by its poor oral bioavailability,
and repeated injection resulted in low compliance for inject-
able administration. Therefore, inhaled administration for
systemic delivery was desirable as a non-invasive route to
improve the bioavailability. Rizatriptan, which displays high
agonist activity at mainly the serotonin 5-HT1B and 5-HT1D
receptor subtypes, is extensively used in the treatment of mi-
graine attack. Although several administrated routes had been
developed, patients with migraine sought rapid relief; there-
fore, a more rapid onset of action was favorable. Thermally
generated aerosols of rizatriptan exhibited excellent pharma-
cokinetic and pharmacological response; therefore, pulmonary
delivery of rizatriptan is thought to provide a rapid pain relief
of migraine.
In the last two decades, studies have utilized engineered
particles to prepare surfactant free MDIs [11–14]. Unlike tra-
ditional micronized particles bymilling, novel particles prepared
by particle engineering techniques may be self-dispersible in
the surfactant free propellants and produce excellent aerosol
performance. Such particle engineering technology in the lit-
erature that includes spray-drying [15–17], spray freeze drying
[18,19], supercritical fluids [20], and controlled crystallization
[16,21–23] classified the engineered particles into three types,
namely, porous particles, particles with surface chemical modi-
fication and with irregular surface, respectively, based upon
mechanisms by which the particles conferred to the en-
hanced performance of dry powder inhalers (DPIs) and MDIs.
For the first two types of particles, numerous studies have dem-
onstrated their applicability to MDIs. For example, several work
reported that hollow porous particles from a pressurized
metered dose inhaler produced excellent in vitro and in vivo
deposition with fine particle fractions up to 70% [24,25]. In ad-
dition, particles coated with HFA-insoluble surfactants [10,26,27]
or modified with polymers such as albumin [28–30] also led
to promising dispersion enhancing effects in HFA propel-
lants. As for the third type of particles, although corrugated
(also called raisin-like or wrinkled) surface has been shown to
lower the interparticulate interactions and increase the FPF from
DPIs [31–34], the feasibility in using wrinkled particles to
improve aerosol performance of MDIs has not been validated
experimentally. Therefore, the objective of the present study
was to produce spray-dried particles with varying surface mor-
phology from smooth to moderately corrugated, and to raisin-
like, and to determine whether the raisin like surface positively
affects the aerosol performance of MDI-formulated spray-
dried particles in the surfactant-free HFA propellants.
2. Materials and methods
2.1. Materials
The buffer phosphate salts, sucrose, trehalose, poly(vinyl
alcohol) 75 and 80 (PVA75 and PVA80), poly(vinyl pyrrolidone)
K15 (PVP15) and leucine were purchased from Sigma Aldrich
(China or UK). Scutellarin was obtained by purifying commer-
cial breviscapine (pharmaceutical grade, Wangzilong Ltd.
Yunnan, China) using Sephadex LH-20 (Amersham Biosci-
ence Ltd. Hong Kong, China) column chromatography, and its
HPLC chromatography purity was determined to be more than
98%. Rizatriptan benzoate was of pharmaceutical grade, ob-
tained from Beijing HvsF United Technology Co. Ltd. (Beijing,
China), Powder bulk density meter (Matuhaku), sodium hyal-
uronate of injection grade obtained fromTonicrays (Zhenjiang,
China) and all other reagents were of analytical grade or HPLC
grade and commercially available. PG semi-automatic minia-
ture propellant filler (Yangzhou Aishaer Aerosol Manufacture
Co., Ltd), HFA 134a was purchased from Xi’an Jinzhu Modern
Chemical Co. Ltd., China, and aluminiumMDI canisters (~20 ml)
fitted with 50 μl metering valves actuators were kindly gifted
by Bespak (UK) and 3M (UK).
2.2. Spray-dried drug particles
The drug particles (Table 1) were prepared by spray-drying using
a Model 191 Büchi mini spray-dryer following the prepara-
tion of feed solution. The higher cyclone designs was used in
our study. The processing parameters comprised a feed rate
of 3 ml/min, an atomizing air-flow rate of 600 l/h and inlet tem-
peratures of 70~140 °C. Outlet temperatures were found to be
Table 1 – Spray-drying parameters and compositions for preparing drug particles with different surface morphology.
Particles Compositions Spray-drying parameters
RLP-C20T70 Rizatriptan 0.8 g, leucine 0.1 g, PVP15 0.1 g Feed concentration of rizatriptan 20 mg/ml, inlet temperature 70 °C
RLP-C20T140 Rizatriptan 0.8 g, leucine 0.1 g, PVP15 0.1 g Feed concentration of rizatriptan 20 mg/ml, inlet temperature 140 °C
RLP-C5T140 Rizatriptan 0.8 g, leucine 0.1 g, PVP15 0.1 g Feed concentration of rizatriptan 5 mg/ml, inlet temperature 140 °C
SLH-C10T70 Scutellarin 0.8 g, leucine 0.1 g, HA 0.1 g Feed concentration of scutellarin 10 mg/ml, inlet temperature 70 °C
SLH-C4T140 Scutellarin 0.8 g, leucine 0.1 g, HA 0.1 g Feed concentration of scutellarin 4 mg/ml, inlet temperature 140 °C
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47~98 °C. Prior to spray-drying, scutellarin and rizatriptan was
dissolved a phosphate buffer (0.1 M, pH 7.3) and purified water,
respectively. Because of the differences in solubility of the two
drugs, the solubility of scutellarin in purified water was smaller
than 1 mg/ml, and therefore, it was dissolved in phosphate
buffer while excipient solutions were prepared by hydrating
polymers or dissolving excipients in purified water. Subse-
quently, the feed solutions were obtained by mixing the drug
and excipient solutions to give a drug concentration of 4–20 mg/
ml (Table 1). Spray-dried particles were obtained in the collection
jar of the spray-dryer.
2.3. Particle morphology and size analysis
Particle size and morphology were investigated using scan-
ning electron microscopy. Powder samples were mounted onto
metal sample plates and coated with gold with a thickness of
3 nm.The samples were then examined under a Jeol JSM 6000F
(Tokyo, Japan), operating at an electrical potential of 12 kV.
Particle size analysis was carried out using a Mastersizer
2000 laser diffraction analyzer (Malvern Instruments, UK).
Several milligrams of the spray-dried powders were dis-
persed in 1 ml of 0.1% w/v lecithin cyclohexane solution. The
particle suspension was sonicated in a water bath for 30 s to
disperse any possible agglomerates before being added to the
sample cell. Particle size distributions were expressed in terms
of volumemedian diameter (VMD) and span.TheVMD was the
diameter at the 50% point of the entire volume distribution
while the span was defined as [D (v, 90)-D (v, 10)]/D (v, 50), where
D (v, 90), D (v, 50), and D (v, 10) were the respective diameters
at 90, 50 and 10% cumulative volumes.
2.4. Density measurements
A 5 cm3 cylinder with an internal diameter of 7.6 mmwas used
in the bulk density determination of spray-dried particles.The
container was filled with accurately weighed particles and the
top was levelled. The density was calculated as the ratio of
the mass to the volume of the sample. The tap density was
determined similarly to the bulk density, but the volume taken
for calculations was that after 500 strokes.
2.5. Preparation of pMDI formulations
Samples (approximately 50 mg) of spray-dried particles were
accurately weighed into individual canisters.The canisters were
stored open in a desiccator containing phosphorus pentox-
ide, thereby exposing the formulation to a relative humidity
of 0% for 24 h, so as to reduce the moisture content to ap-
proximately 1.5% (w/w) (thermogravimetric analysis (TGA)
results showed that the moisture content of scutellarin or
rizatriptan particles was at approximately 1.5% (w/w) upon ex-
posure in a desiccator containing phosphorus pentoxide for
a period of 24 h or longer). Subsequently, the aluminum can-
isters were capped by crimping metering valves into place and
filling through the valves with ~10 g of HFA 134a. The integ-
rity of the crimping of the canisters was tested by monitoring
the weight change, when a weight change less than 10 mg over
3 days was regarded as meeting the integrity requirement.
2.6. Analysis of the samples by HPLC
The amount of scutellarin and rizatriptan in the samples col-
lected in the cups of the NGI was determined using a Waters
HPLC system, which included aWaters 717 plus autosampler,
Waters 2487 Dual λ Absorbance Detector, Multi δ fluores-
cence detector,Waters 600 Controller pump and an Empower
software system. Each sample was injected onto a C18 Apollo
column (150 mm × 4.6 mm, 5 μm, Alltech Associates Inc.)
equipped with a Phenomenex guard column (Phenomenex Inc.)
for better analyzing results. Each drug solution was analyzed
with an aliquot of 10 μL being applied to the column main-
tained at 40 °C, eluted at a flow rate 1 ml/min. For assaying
scutellarin, an isocratic mobile phase system consisting of ace-
tonitrile and 0.1% acetic acid aqueous solution (17:83) and a
detection wavelength of 335 nm was employed, while for the
analysis of rizatriptan, fluorescence detection was performed
at an excitation wavelength of 225 nm and an emission wave-
length of 360 nm, and the mobile phase was composed of 0.05%
(v/v) triethylamine in water (adjusting to pH 2.75 with 85%
phosphoric acid) and acetonitrile (90:10, v/v). Before the mea-
surements, both methods were validated in terms of specificity,
linearity, precision, recovery, limit of detection (LOD) and limit
of quantification (LOQ).
2.7. Determination of uniformity of delivered dose
The dose delivered through the actuation of a canister was de-
termined using a dose collection apparatus (Copley Scientific
Ltd., UK) according to the protocol detailed in the European
Pharmacopoeia. Briefly, an inhaler was shaken for 5 s, dis-
charged 1–3 times to waste with >5 s between each activation
and the device washed using purified water; subsequently the
inverted inhaler was fired to the apparatus and the amount
of active substance quantitatively collected for assaying. The
dose uniformity of scutellarin and rizatriptan formulations were
determined based on variations in each puff. Four puffs were
assayed for the uniformity of delivered dose. Firstly, 20 ml of
deionized water was used to dissolve drugs, and then the ac-
tuator and valve stem were washed and dried after priming
to waste and before the sampling to prevent drug being carried
over.
2.8. In vitro deposition tests
An in vitro aerodynamic assessment of fine particles of
scutellarin and rizatriptan MDI was performed using a next
generation pharmaceutical impactor (NGI) (MSP Corporation,
Minneapolis, USA). Each canister was mounted onto the end
of the throat via a rubber mouthpiece adapter and an actua-
tor.The vacuum pump was adjusted so that an air flow of 30 l/
min was established through the NGI setup and the MDI was
discharged 3 times to waste prior to each test. The vacuum
pump was switched on and the MDI actuated once only for
each formulation. After actuation, the pump was left on for a
further 5 s, air flow was then stopped and the setup dis-
mantled. 20 mL of deionized water was used to dissolve the
drug deposits on the NGI parts for assay.The actuator and stem
were washed after priming and before the sampling to prevent
drug being carried over.
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Following the recovery of the drug solution from each col-
lection cup, the amount of the active ingredient in the cups
was determined using the above mentioned assays. The fine
particle dose was calculated as the recovered dose of active
ingredient from stage 3 to micro-orifice collector (MOC) of the
NGI. The FPF was defined as the fine particle dose divided by
the whole dose of the drug found in the impactor (including
the throat). The recovery of drug found in the impactor rela-
tive to the emitted dose varied from 89.7% to 101.6%.The mass
median aerodynamic diameter (MMAD) was the diameter at
the 50% cumulative percentage while the geometric stan-
dard deviation (GSD) was defined as the ratio of the diameter
at the 84.1% cumulative percentage to the 50%.
3. Results and discussion
3.1. Physical characteristics of spray-dried particles
Spray-drying has been utilized for the preparation of
microparticles with controlled particle morphology and suit-
able for pulmonary drug delivery [15,17]. Previous studies
showed that varying the feed solvent [35,36] and adjusting the
outlet drying temperature [37] affected particle morphology,
and concomitantly manipulating feed concentration and at-
omization rate might produce particles with different degrees
of surface corrugation [1,38]. In the present study, a prelimi-
nary study had tested the effect of spray-drying parameters
such as inlet temperature, feed concentration, feed rate and
atomizing pressure on particle surface morphology and the
results (data not shown) indicated that inlet temperature, feed
concentration and feed rate markedly affected the surface
morphology, with the feed rate also dramatically influencing
the particle size. As a result, in order to produce particles with
similar particle size but different surface morphology, only the
parameters of inlet temperature and feed concentration were
manipulated in the further study, while feed rate and atom-
izing pressure were maitained constant.
Apart from spray-drying parameters, including excipients
such as lactose,Tween 20 [32,37,39] and leucine [40] to the feed
solution might favor to yield particles with rougher surfaces.
As such, a pilot study was carried out to test the effect of various
excipients on the surface morphology of rizatriptan particles
using an inlet temperature of 90 °C and results showed that
leucine, PVA75, PVA 80, PVP15, albumin and lecithin in-
creased the degree of corrugation while HA, sucrcose, lactose,
trehalose and dextran negatively affect the formation of cor-
rugated particles (data not shown). Based upon the above
findings, two compositions of the model drugs (Table 1)
were spray-dried, and SEM results (Fig. 1 and Table 2) showed
that the surface morphology of spray-dried particles could vary
from smooth to moderately raisin-like, and to raisin-like de-
pending upon spray-drying parameters and preparation
compositions. In particular, leucine appeared to be an excel-
lent promoter for the production of wrinkled particles and it
could overcome the negative effect of HA on the formation of
corrugated surface.
The mechanism by which spray-drying parameters and feed
compositions affect the particle surface morhology is not en-
tirely clear. A previous study suggested it might be related to
Peclet numbers which represent the ratio between convec-
tion and diffusion, and compositions with higher Peclet
numbers tended to form particles with irregular surface [17].
The Peclet number is influenced by the evaporation rate and
Fig. 1 – Scanning electron micrographs of spray-dried particles (a) RLP-C20T70, (b) RLP-C20T140, (c) RLP-C5T140, (d) SLH-C10T70,
and (e) SLH-C4T140.
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the latter is dictated by the combination of feed composition
and spray-drying parameters [17]. Therefore, it is conceivable
that an increase in inlet temperature favors the formation of
wrinkled particles since the Peclet number may increase with
an increase in evaporation rate of sprayed droplets as a result
of high inlet temperature. In addition, the feed concentration
and solubility were also reported to affect the particle
morphology. Previously, it was suggested that a high feed con-
centration and/or low solubility favored the formation of a very
early shell on the droplet surface [12,41,42], and the raisin-
like particles may be produced when the shell was shriveled.
In the present study, rizatriptan had a higher solubility than
scutellarin, and hence it was more difficult to be spray-dried
to produce particles with raisin-like surface. The solubility of
rizatriptan is 42 mg/mL, whereas it was smaller than 1 mg/
ml for scutellarin. Therefore, the aqueous phases used for
dissolving the two drugs were different; scutellarin was firstly
dissolved in phosphate buffer, and then diluted to certain con-
centrations. Our results from rizatriptan demonstrated that
phosphate buffer had no effects on the inhalable activity.
The particle size and size distribution of the spray-dried par-
ticles are shown in Table 2. The volume median diameters
(VMD) of all spray-dried batches were found to be between 2.39
and 3.61 μm. In addition, the particle size span for these batches
laid between 1.37 and 1.60, which indicates that all the powders
exhibited a moderate degree of monodispersity. The majority
of particles in these batches were ≤10.0 μm.The bulk and tap
density (Table 2) were found to relate to the surface morphol-
ogy in general, with the raisin-like particles always having the
highest bulk and tap density when the compositions were the
same. The relatively high density of raisin-like particles indi-
cated that such particles were nonporous [43].
3.2. Deposition of MDI-formulated particles
After filling HFA 134a, RLP-C20T70 particles were visually found
to dramatically flocculate and other particles with slightly cor-
rugated surface moderately flocculated, while apparent
flocculation were not observed for those raisin-like particles
(data not shown). In the present study, the amount of drug that
remained in the actuator device varied from 14% to 23% of the
total amount of ex-valve dose. In addition, the coefficients of
variation of delivered dose (collected drug amount in the dose
collection apparatus) appeared to be related to the particle mor-
phology. Raisin-like particle based formulations always had a
better dose uniformity while smooth or less corrugated par-
ticle containing formulations resulted in variations of over 10%
(Table 3), The physical stability of the MDI suspensions after
shaking partly depended on the surface morphology; there-
fore, deposition experiment was performed immediately after
shaking to avoid the variation in different formulations. For
example, the mean delivered doses of rizatriptan from three
formulations, RLP-C20T70, RLP-C20T140 and RLP-C5T140 (each
of which comprised three independent samples), were found
to be 202.2 ± 22.5 μg, 196.8 ± 24.5 μg, 196.0 ± 11.5 μg per actua-
tion, respectively. Due to the relatively large variations in the
delivered dose, the total recovered fractions from NGI were nor-
malized to 100% for each individual deposition test.
The in vitro deposition results of rizatriptan MDI formula-
tions are shown in Table 3 and Fig. 2.The aerosol performance
of MDIs with the same compositions but different spray-
drying parameters was found to bemarkedly different.The drug
fractions recovered from stage 3 to MOC of the NGI (fine par-
ticle fraction, FPF) for RLP-C20T70, RLP-C20T140 and RLP-
C5T140 MDI formulations were found to be about 9.2, 20.2 and
30.8%, respectively, and FPF was inversely related to the cor-
responding MMAD. In general, raisin-like particles conferred
the highest FPF and the lowest MMAD, while spherical par-
ticles with broadly smooth surface had the lowest FPF and the
highest MMAD. The apparent higher MMAD could be due to
the presence of agglomerates in the aerosol of smooth par-
ticles. It has been shown that the inter-particular forces between
smooth particles are higher for DPI formulations. Another pos-
sible reason is that smooth particles have a higher particle
density.
Deposition results (Table 3) of scutellarin MDI formula-
tions also indicated that raisin-like particle based MDI produced
significantly better aerodynamic performance in terms of FPF
(P < 0.01, Mann–Whitney test) and MMAD (P < 0.05, Mann–
Whitney test) relative to the formulation of moderately
corrugated particles.
The above results showed that raisin-like particle basedMDIs
always exhibited better aerosol performances in terms of dose
Table 2 – Particle properties of spray-dried rizatriptan and scutellarin particles.






RLP-C20T70 Spherical and broadly smooth 3.61 1.37 0.08 0.14
RLP-C20T140 Slightly raisin like 2.73 1.42 0.09 0.16
RLP-C5T140 Raisin like 2.61 1.51 0.13 0.18
SLH-C10T70 Smooth with dimples 3.20 1.60 0.15 0.24
SLH-C4T140 Raisin like 2.39 1.40 0.21 0.27
a See Table 1 for the compositions.
Table 3 – Deposition results of spray-dried rizatriptan






RLP-C20T70 202.2 ± 22.5 4.96 ± 0.12 1.24 ± 0.61
RLP-C20T140 196.8 ± 24.5 3.48 ± 0.10 1.83 ± 0.31
RLP-C5T140 196.0 ± 11.5 2.63 ± 0.30 2.31 ± 0.09
SLH-C10T70 234.3 ± 28.7 2.46 ± 0.40 2.15 ± 0.39
SLH-C4T140 243.1 ± 13.2 1.87 ± 0.04 2.00 ± 0.02
a See Table 1 for the compositions.
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uniformity, fine particle fractions and MMAD relative to the for-
mulations of the corresponding smooth or slightly corrugated
particles. The dispersions of raisin-like particles in HFA pro-
pellants gave MMAD less than 3 μmand therefore such aerosols
may deposit in the deep lung, suitable for pulmonary deliv-
ery of rizatriptan and scutellarin intended to elicit systemic
effects [44,45]. In addition, a previous study [45] showed hy-
aluronic acid (HA) may enhance pulmonary absorption of
scutellarin due to its mucoadhesive properties.Although spray-
dried scutellarin-HA particles appeared not to be well dispersed
in an HFA propellant (data not shown), the wrinkled particles
spray-dried in the presence of leucine could enhance the
dispersibility, leading to high FPF.
The better performances conferred by wrinkled particles
could not be explained by the coating effect of excipients. For
example, leucine is an excellent coating excipient in enhanc-
ing the particle dispersibility in DPIs [38]. However, leucine
containing particles with smooth surface in the present study
produced a poor aerosol performance in MDIs. Particulate
aggregation/flocculation is common in MDI suspension for-
mulations, and the dispersibility of particles is essentially
dependent upon the physicochemical properties of the ma-
terial interface with the propellant. The incompatibility of
coating ingredients on the particle surface with the disper-
sion medium may alter interparticulate cohesive forces,
resulting in different aerosol performances between DPI and
MDI formulations.The enhanced aerosol performance of raisin-
like particles over the smooth or slightly corrugated particles
may be explained by the reduction in the contact area of
between particles, which would in turn increase the average
distance between particles. Such a rationale has been pro-
posed by Chew and colleagues [31,38] to account for the
reduction in the interparticulate interactions and the in-
crease in the FPF of corrugated particles from DPIs. Indeed,
increasing the average distance between particles would dra-
matically decrease van derWaal’s and electrostatic attraction
forces for particles suspended in propellant medium.
4. Conclusion
In this study, the effects of spray-drying parameters and feed
compositions on the formation of raisin-like particles were in-
vestigated, and the results indicated that the parameters of inlet
temperature, feed concentration and inclusion of certain ex-
cipients to the feed solution could affect the surfacemorphology
of spray-dried particles. In particular, the presence of leucine
in the feed solution favored to produce raisin-like particles when
spray-drying was carried out at a high inlet temperature. In
addition, the present results suggested that MDIs formulated
with raisin-like particles afforded a better aerosol perfor-
mance over those counterparts with smooth or slightly
corrugated particles.
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